EUVIMEDEUVIMED entdecken
Crossref

Mechanisms of Fuling Zexie decoction against metabolic dysfunction-associated steatotic liver disease: Integrative metabolomics, gut microbiota and serum pharmacochemistry

Peng-Quan Wang, Huan Yang, Yan-Mei Tang, Yu-Xuan Tao, Shao-Cong Han, Qi-Di Zhou, Jie Yu, Xing-Xin Yang

World Journal of Gastroenterology · 07.01.2027 · 33 (1)

DOI: 10.3748/wjg.123034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Gastroenterology, online erschienen am 07.01.2027. Verfasst von Peng-Quan Wang und 7 weiteren Autor:innen. Die Arbeit nennt 85 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Metabolic dysfunction-associated steatotic liver disease (MASLD) currently lacks specific therapeutic options. Fuling Zexie decoction (FZD) is a Chinese herbal formula that shows potential for treating MASLD, but its mechanism and active ingredients remain unclear. AIM To determine the mechanism and active ingredients of FZD against MASLD. METHODS Free fatty acid-stimulated steatotic HepG2 cells and high-fat diet-fed MASLD rats were used to assess the functionality of FZD. To investigate the mechanisms by which FZD affects endogenous metabolites and intestinal microbiota in rats, a combination of metabolomics and 16S rRNA sequencing was utilized. Serum pharmacochemistry-metabolomics integration identified FZD’s active ingredients and core targets, while molecular docking and cellular experimentation were utilized to validate the association of these ingredients and targets. RESULTS FZD ameliorated hepatic steatosis and hepatocellular injury in rats with MASLD, ameliorated serum and hepatic lipid levels, augmented antioxidant capacity, and mitigated inflammatory responses. Mechanistically, FZD restored 226 endogenous metabolites and regulated 17 metabolic pathways. This included reducing the Firmicutes/Bacteroidota ratio and diminishing the levels of potentially harmful microbes (Unclassified_f_Lachno spiraceae , Candidatus Saccharimonas , and Turicibacter ). A total of 39 FZD-originated constituents were detected in the serum. Among these, 24 were recognized as key pharmacodynamic constituents that modulated 17 targets, 10 metabolic pathways, and 18 endogenous metabolites. The key pharmacodynamic compound group downregulated the expression of NOS2 , MAOA , and MIF , thereby alleviating hepatic steatosis. CONCLUSION These results demonstrate that FZD alleviates MASLD by regulating 10 metabolic pathways, decreasing the abundance of Unclassified_f_Lachnospiraceae , Candidatus Saccharimonas , and Turicibacter , and normalizing 18 endogenous metabolite levels, which may be primarily attributed to the 24 FZD-derived active ingredients.

Zitieren

APA

Wang, P., Yang, H., Tang, Y., Tao, Y., Han, S., Zhou, Q., Yu, J., & Yang, X. (2027). Mechanisms of Fuling Zexie decoction against metabolic dysfunction-associated steatotic liver disease: Integrative metabolomics, gut microbiota and serum pharmacochemistry. World Journal of Gastroenterology, 33(1). https://doi.org/10.3748/wjg.123034

Vancouver

Wang P, Yang H, Tang Y, Tao Y, Han S, Zhou Q, et al. Mechanisms of Fuling Zexie decoction against metabolic dysfunction-associated steatotic liver disease: Integrative metabolomics, gut microbiota and serum pharmacochemistry. World Journal of Gastroenterology. 2027;33(1). doi:10.3748/wjg.123034

BibTeX
@article{Wang2027,
  author = {Wang, Peng-Quan and Yang, Huan and Tang, Yan-Mei and Tao, Yu-Xuan and Han, Shao-Cong and Zhou, Qi-Di and Yu, Jie and Yang, Xing-Xin},
  title = {Mechanisms of Fuling Zexie decoction against metabolic dysfunction-associated steatotic liver disease: Integrative metabolomics, gut microbiota and serum pharmacochemistry},
  journal = {World Journal of Gastroenterology},
  year = {2027},
  volume = {33},
  number = {1},
  doi = {10.3748/wjg.123034}
}
Kostenlos starten →